Twist Bioscience Raises Additional $27 Million

posted in: News | 0

Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $27 million in venture financing. This close, combined with the $33 million announced in March 2017, completes the $60 Read More…

ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010

posted in: News | 0

ARMO BioSciences, Inc., a late-stage immuno-oncology  company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with FOLFOX chemotherapy for the treatment of patients with advanced pancreatic cancer. These data are being presented in Read More…

ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors

posted in: News | 0

ARMO BioSciences, Inc., a late-stage immuno-oncology  company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with immune checkpoint inhibitors for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and metastatic Read More…

Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers

posted in: News | 0

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has licensed LMB-100, a next-generation immunotoxin, from the Center for Cancer Research (CCR) at the NCI, part Read More…

1 2 3 4 8